Indication

Esophageal Squamous Cell Carcinoma With Negative Lymph Nodes

1 clinical trial

1 product

Clinical trial

S-1 Combined With Tislelizumab in Patients With Primary Residual Node-negative Esophageal Squamous Cell Carcinoma (ESCC) After Radical Resection With Neoadjuvant Immunotherapy Combined With Chemotherapy, PHASE II STUDY

Status: Recruiting, Estimated PCD: 2027-04-30

Product